Voyager Therapeutics Stock Today
| VYGR Stock | USD 5.78 0.11 1.94% |
Performance0 of 100
| Odds Of DistressLess than 1
|
Voyager Therapeutics is selling at 5.78 as of the 28th of November 2024; that is 1.94 percent increase since the beginning of the trading day. The stock's lowest day price was 5.67. Voyager Therapeutics has a very small chance of experiencing financial distress in the next few years, but has generated negative returns over the last 90 days. Equity ratings for Voyager Therapeutics are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 30th of August 2024 and ending today, the 28th of November 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 11th of November 2015 | Category Healthcare | Classification Health Care |
Voyager Therapeutics, Inc., a gene therapy company, focuses on the development of treatments and next-generation platform technologies. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Cambridge, Massachusetts. Voyager Therapeut operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. The company has 54.63 M outstanding shares of which 2.95 M shares are at this time shorted by private and institutional investors with about 3.55 trading days to cover. More on Voyager Therapeutics
Moving together with Voyager Stock
Moving against Voyager Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Voyager Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| Chief CEO | Trista Morrison | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Thematic Idea | Pharmaceutical Products (View all Themes) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Old Name | Voyager Digital (Canada) Ltd | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Biotechnology, NASDAQ Composite, Pharmaceutical Products, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsVoyager Therapeutics can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Voyager Therapeutics' financial leverage. It provides some insight into what part of Voyager Therapeutics' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Voyager Therapeutics (VYGR) is traded on NASDAQ Exchange in USA. It is located in 75 Hayden Avenue, Lexington, MA, United States, 02421 and employs 162 people. Voyager Therapeutics is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a current market capitalization of 309.73 M. Voyager Therapeutics conducts business under Biotechnology sector and is part of Health Care industry. The entity has 54.63 M outstanding shares of which 2.95 M shares are at this time shorted by private and institutional investors with about 3.55 trading days to cover.
Voyager Therapeutics currently holds about 148.06 M in cash with 77.92 M of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.83.
Check Voyager Therapeutics Probability Of Bankruptcy
Ownership AllocationVoyager Therapeutics shows a total of 54.63 Million outstanding shares. Over half of Voyager Therapeutics' outstanding shares are owned by institutional holders. These institutional holders are typically referred to as corporate investors that take positions in a given instrument to benefit from reduced trade commissions. Please note that no matter how many assets the company owns, if the real value of the company is less than the current market value, you may not be able to make money on it.
Check Voyager Ownership Details
Voyager Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Bank Of America Corp | 2024-06-30 | 648.8 K | |
| Vestal Point Capital Lp | 2024-06-30 | 600 K | |
| Federated Hermes Inc | 2024-09-30 | 551.4 K | |
| Aqr Capital Management Llc | 2024-06-30 | 502.4 K | |
| Goldman Sachs Group Inc | 2024-06-30 | 444 K | |
| Prudential Financial Inc | 2024-09-30 | 412.4 K | |
| Northern Trust Corp | 2024-09-30 | 406.4 K | |
| Woodline Partners Lp | 2024-06-30 | 300 K | |
| Bank Of New York Mellon Corp | 2024-06-30 | 294.4 K | |
| Blackrock Inc | 2024-06-30 | 5.3 M | |
| Armistice Capital, Llc | 2024-09-30 | 5.2 M |
Voyager Therapeutics Historical Income Statement
Voyager Stock Against Markets
Voyager Therapeutics Corporate Management
| Sandrock MD | CEO Pres | Profile | |
| Dr MBA | Chief Officer | Profile | |
| JD Esq | Chief Officer | Profile | |
| Todd Carter | Chief Officer | Profile |
Additional Tools for Voyager Stock Analysis
When running Voyager Therapeutics' price analysis, check to measure Voyager Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Voyager Therapeutics is operating at the current time. Most of Voyager Therapeutics' value examination focuses on studying past and present price action to predict the probability of Voyager Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Voyager Therapeutics' price. Additionally, you may evaluate how the addition of Voyager Therapeutics to your portfolios can decrease your overall portfolio volatility.